Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II
This perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-04-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2079-6382/7/2/35 |
| _version_ | 1811242974629068800 |
|---|---|
| author | Expert round table on acceptance and re-implementation of bacteriophage therapy Wilbert Sybesma Christine Rohde Pavol Bardy Jean-Paul Pirnay Ian Cooper Jonathan Caplin Nina Chanishvili Aidan Coffey Daniel De Vos Amber Hartman Scholz Shawna McCallin Hilke Marie Püschner Roman Pantucek Rustam Aminov Jiří Doškař D. İpek Kurtbӧke |
| author_facet | Expert round table on acceptance and re-implementation of bacteriophage therapy Wilbert Sybesma Christine Rohde Pavol Bardy Jean-Paul Pirnay Ian Cooper Jonathan Caplin Nina Chanishvili Aidan Coffey Daniel De Vos Amber Hartman Scholz Shawna McCallin Hilke Marie Püschner Roman Pantucek Rustam Aminov Jiří Doškař D. İpek Kurtbӧke |
| author_sort | Expert round table on acceptance and re-implementation of bacteriophage therapy |
| collection | DOAJ |
| description | This perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build on the previously made recommendations and specifically address how the Nagoya Protocol might impact the further development of bacteriophage therapy. By reviewing a number of recently conducted case studies with bacteriophages involving patients with bacterial infections that could no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and significance of the development of international guidelines and frameworks that might facilitate the legal and effective application of bacteriophage therapy by physicians and the receiving patients. Additionally, we list and comment on several recently started and ongoing clinical studies, including highly desired double-blind placebo-controlled randomized clinical trials. We conclude with an outlook on how recently developed DNA editing technologies are expected to further control and enhance the efficient application of bacteriophages. |
| first_indexed | 2024-04-12T13:59:48Z |
| format | Article |
| id | doaj.art-6e88c0e5bb4b42dcb8c67d614c8a9f06 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-04-12T13:59:48Z |
| publishDate | 2018-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-6e88c0e5bb4b42dcb8c67d614c8a9f062022-12-22T03:30:14ZengMDPI AGAntibiotics2079-63822018-04-01723510.3390/antibiotics7020035antibiotics7020035Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part IIExpert round table on acceptance and re-implementation of bacteriophage therapy0Wilbert Sybesma1Christine Rohde2Pavol Bardy3Jean-Paul Pirnay4Ian Cooper5Jonathan Caplin6Nina Chanishvili7Aidan Coffey8Daniel De Vos9Amber Hartman Scholz10Shawna McCallin11Hilke Marie Püschner12Roman Pantucek13Rustam Aminov14Jiří Doškař15D. İpek Kurtbӧke16<email>Phage_therapy@pha.ge</email>; <email>wilbert.sybesma@gmail.com</email> (W.S.); <email>ikurtbok@usc.edu.au</email> (D.I.K.).Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, CH-8008 Zürich, SwitzerlandLeibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, D-38124 Braunschweig, GermanyDepartment of Experimental Biology, Faculty of Science, Masaryk University, Brno 611 37, Czech RepublicLaboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, B-1120 Brussels, BelgiumSchool of Pharmacy and Biomolecular Sciences and School of Environment & Technology, University of Brighton, Brighton BN2 4GJ, UKSchool of Pharmacy and Biomolecular Sciences and School of Environment & Technology, University of Brighton, Brighton BN2 4GJ, UKEliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi 0160, GeorgiaDepartment of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork T12 P928, UKLaboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, B-1120 Brussels, BelgiumLeibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, D-38124 Braunschweig, GermanyDepartment of Fundamental Microbiology, University of Lausanne, CH-1015 Lausanne, SwitzerlandLeibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, D-38124 Braunschweig, GermanyDepartment of Experimental Biology, Faculty of Science, Masaryk University, Brno 611 37, Czech RepublicSchool of Medicine & Dentistry, University of Aberdeen, Aberdeen AB25 2ZD, UKDepartment of Experimental Biology, Faculty of Science, Masaryk University, Brno 611 37, Czech RepublicGeneCology Research Centre and the Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Maroochydore DC, QLD 4558, AustraliaThis perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build on the previously made recommendations and specifically address how the Nagoya Protocol might impact the further development of bacteriophage therapy. By reviewing a number of recently conducted case studies with bacteriophages involving patients with bacterial infections that could no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and significance of the development of international guidelines and frameworks that might facilitate the legal and effective application of bacteriophage therapy by physicians and the receiving patients. Additionally, we list and comment on several recently started and ongoing clinical studies, including highly desired double-blind placebo-controlled randomized clinical trials. We conclude with an outlook on how recently developed DNA editing technologies are expected to further control and enhance the efficient application of bacteriophages.http://www.mdpi.com/2079-6382/7/2/35antibiotic resistancebacteriophagesbacteriophage therapyNagoya ProtocolCRISPR CAS |
| spellingShingle | Expert round table on acceptance and re-implementation of bacteriophage therapy Wilbert Sybesma Christine Rohde Pavol Bardy Jean-Paul Pirnay Ian Cooper Jonathan Caplin Nina Chanishvili Aidan Coffey Daniel De Vos Amber Hartman Scholz Shawna McCallin Hilke Marie Püschner Roman Pantucek Rustam Aminov Jiří Doškař D. İpek Kurtbӧke Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II Antibiotics antibiotic resistance bacteriophages bacteriophage therapy Nagoya Protocol CRISPR CAS |
| title | Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II |
| title_full | Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II |
| title_fullStr | Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II |
| title_full_unstemmed | Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II |
| title_short | Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II |
| title_sort | silk route to the acceptance and re implementation of bacteriophage therapy part ii |
| topic | antibiotic resistance bacteriophages bacteriophage therapy Nagoya Protocol CRISPR CAS |
| url | http://www.mdpi.com/2079-6382/7/2/35 |
| work_keys_str_mv | AT expertroundtableonacceptanceandreimplementationofbacteriophagetherapy silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT wilbertsybesma silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT christinerohde silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT pavolbardy silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT jeanpaulpirnay silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT iancooper silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT jonathancaplin silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT ninachanishvili silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT aidancoffey silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT danieldevos silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT amberhartmanscholz silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT shawnamccallin silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT hilkemariepuschner silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT romanpantucek silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT rustamaminov silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT jiridoskar silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii AT dipekkurtböke silkroutetotheacceptanceandreimplementationofbacteriophagetherapypartii |